# Phase 3 pneumonia trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 3 for pneumonia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 pneumonia trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/pneumonia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07900373 | Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 | Not yet recruiting | Pneumocystis Jirovecii Pneumonia | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900373) |
| September 22, 2026 | NCT07834346 | CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL | Hellenic Institute for the Study of Sepsis | Phase 3 | Recruiting | Sepsis | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834346) |
| June 24, 2026 | NCT07665788 | Inhaled Amikacin Versus Placebo in Patients With Ventilator-associated Tracheobronchitis | University Hospital, Tours | Phase 3 | Not yet recruiting | Ventilator-Associated Pneumonia, Ventilator-Associated Tracheobronchitis | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665788) |
| May 22, 2026 | NCT07604103 | Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute... | University of Brawijaya | Phase 3 | Recruiting | Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604103) |
| January 20, 2026 | NCT07352865 | Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Psittacosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07352865) |
| January 20, 2026 | NCT07351500 | Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Influenza | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351500) |
| September 3, 2025 | NCT07152613 | Corticosteroids for PJP in Non-HIV Immunocompromised Adults | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Pneumocystis Jiroveci Pneumonia | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07152613) |
| September 3, 2025 | NCT07152600 | Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Adenovirus Infections, Human | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07152600) |
| June 10, 2025 | NCT07013474 | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | Pfizer | Phase 3 | Recruiting | COVID-19 Infection | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07013474) |
| November 29, 2024 | NCT06710080 | Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia | Ottawa Heart Institute Research Corporation | Phase 3 | Recruiting | Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710080) |
| November 7, 2024 | NCT06679140 | A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are... | Pfizer | Phase 3 | Recruiting | COVID-19 SARS-CoV-2 Infection | 2,330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06679140) |
| June 25, 2024 | NCT06472219 | PREDICATE Trial For Respiratory Tract Infections | The University of Hong Kong | Phase 3 | Recruiting | Respiratory Tract Infections | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06472219) |
| February 21, 2024 | NCT06269900 | Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype | Nantes University Hospital | Phase 3 | Recruiting | Hospital Acquired Pneumonia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06269900) |
| January 29, 2024 | NCT06229288 | Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a... | Nantes University Hospital | Phase 3 | Recruiting | Community-acquired Pneumonia | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06229288) |
| November 18, 2023 | NCT06134492 | Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL | Jena University Hospital | Phase 3 | Recruiting | Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex, Hospital-acquired... | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06134492) |
| November 13, 2023 | NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy | University of Sydney | Phase 3 | Recruiting | Lung Cancer | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06127654) |
| June 15, 2023 | NCT05903352 | Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Community-Acquired Pneumonia | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05903352) |
| May 8, 2023 | NCT05848713 | AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia | University of Manitoba | Phase 3 | Recruiting | Community-acquired Pneumonia | 4,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05848713) |
| May 6, 2023 | NCT05843786 | Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | Hospices Civils de Lyon | Phase 3 | Recruiting | Pneumonia, Ventilator-Associated | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05843786) |
| February 10, 2023 | NCT05722938 | Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) | Biotest | Phase 3 | Recruiting | Community-acquired Pneumonia | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05722938) |
| January 25, 2023 | NCT05696093 | Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Ventilator Associated Pneumonia | 628 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05696093) |
| April 20, 2021 | NCT04851015 | Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia | Sponsor not shown (see the record) | Phase 3 | Recruiting | Pneumocystis, Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections, Pneumocystis Carinii... | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04851015) |
| May 11, 2020 | NCT04381936 | Randomised Evaluation of COVID-19 Therapy | University of Oxford | Phase 3 | Recruiting | Pneumonia | 70,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04381936) |
| April 13, 2016 | NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | UMC Utrecht | Phase 3 | Recruiting | Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia... | 20,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02735707) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Nantes University Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| UMC Utrecht | 1 |
| The University of Hong Kong | 1 |
| Hellenic Institute for the Study of Sepsis | 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 1 |
| Hospices Civils de Lyon | 1 |
| University of Oxford | 1 |
| University of Manitoba | 1 |
| University Hospital, Tours | 1 |
| Ottawa Heart Institute Research Corporation | 1 |
| University of Brawijaya | 1 |
| Jena University Hospital | 1 |
| University of Sydney | 1 |
| Biotest | 1 |

## By country

| Country | Trials |
| --- | --- |
| France | 10 |
| Canada | 6 |
| Spain | 6 |
| Belgium | 5 |
| Germany | 5 |
| United States | 5 |
| Brazil | 4 |
| Australia | 3 |
| Czechia | 3 |
| Japan | 3 |
| Netherlands | 3 |
| Romania | 3 |
| United Kingdom | 3 |
| Greece | 3 |
| South Africa | 3 |
| Mexico | 3 |
| Argentina | 3 |
| Estonia | 2 |
| Finland | 2 |
| Hungary | 2 |
| India | 2 |
| Ireland | 2 |
| Israel | 2 |
| Italy | 2 |
| Nepal | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Paving contractors in the United States](https://specstream.ai/data/businesses/paving-contractors/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
